Literature DB >> 1933482

Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.

L A Leone1, P A Meitner, T J Myers, W R Grace, W H Gajewski, H J Fingert, B Rotman.   

Abstract

The potential clinical usefulness of the fluorescent cytoprint assay (FCA) was assessed retrospectively in 73 cancer patients by correlating individual tumor chemosensitivity in vitro with responses to chemotherapy. The data show that the FCA has a sensitivity of 98%, specificity of 81%, and predictive accuracies of 85% and 97% for positive and negative clinical responses, respectively.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1933482     DOI： 10.3109/07357909109018947

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  10 in total

1.  In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.

Authors:  B Küpeli; S Baltaci; M Beksac; O Süzer; S Küpeli; O Göğüs
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Representativeness of microorgans from human colorectal tumors.

Authors:  S D Finkelstein; R Sayegh; P A Swalsky; A Bakker; R Guzman; B Rotman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

3.  Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.

Authors:  S Küpeli; M Beksac; B Küpeli; S Baltaci; O Süzer
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 4.  Prediction of response to drug therapy of cancer. A review of in vitro assays.

Authors:  W T Bellamy
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

5.  A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Authors:  S Bahram Bahrami; Beryl A Hatton; Richard A Klinghoffer; Jason P Frazier; Alicia Moreno-Gonzalez; Andrew D Strand; William S Kerwin; Joseph R Casalini; Derek J Thirstrup; Sheng You; Shelli M Morris; Korashon L Watts; Mandana Veiseh; Marc O Grenley; Ilona Tretyak; Joyoti Dey; Michael Carleton; Emily Beirne; Kyle D Pedro; Sally H Ditzler; Emily J Girard; Thomas L Deckwerth; Jessica A Bertout; Karri A Meleo; Ellen H Filvaroff; Rajesh Chopra; Oliver W Press; James M Olson
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 6.  Ex vivo programmed cell death and the prediction of response to chemotherapy.

Authors:  Robert A Nagourney
Journal:  Curr Treat Options Oncol       Date:  2006-03

Review 7.  Prediction of individual response to anticancer therapy: historical and future perspectives.

Authors:  Florian T Unger; Irene Witte; Kerstin A David
Journal:  Cell Mol Life Sci       Date:  2014-11-12       Impact factor: 9.261

Review 8.  Benefits of functional assays in personalized cancer medicine: more than just a proof-of-concept.

Authors:  Christophe Bounaix Morand du Puch; Mathieu Vanderstraete; Stéphanie Giraud; Christophe Lautrette; Niki Christou; Muriel Mathonnet
Journal:  Theranostics       Date:  2021-09-21       Impact factor: 11.556

9.  Cytotoxicity of unsaturated fatty acids in fresh human tumor explants: concentration thresholds and implications for clinical efficacy.

Authors:  David E Scheim
Journal:  Lipids Health Dis       Date:  2009-12-15       Impact factor: 3.876

Review 10.  Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients.

Authors:  Engin Ulukaya; Didem Karakas; Konstantinos Dimas
Journal:  Medicina (Kaunas)       Date:  2021-06-19       Impact factor: 2.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.